ArticleCrohn's & colitis 3602026
Genetic proof of herpesviruses CMV, EBV and HHV-6 in intestinal biopsies from patients with inflammatory bowel diseases: prevalence and disease characteristics.
Article in Crohn's & colitis 360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While the clinical relevance of cytomegalovirus (CMV) for inflammatory bowel disease (IBD) patients remains controversial, the role of related Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6) is unknown. The aim of this retrospective study was to determine the prevalence of CMV, EBV, and HHV-6 DNA in the intestinal mucosa of IBD patients, and to identify potential risk factors and associations with disease characteristics. Methods: Any IBD patient who underwent endoscopy with mucosal biopsy for virologic assessment at Heidelberg University Hospital from December 2018 to September 2020 was eligible. DNA of CMV, EBV, and HHV-6 was determined by polymerase chain reaction. Results: A total of 230 patients were included (123 male, median age 37 years). Ulcerative colitis was diagnosed in 146 patients (63.5%), Crohn's disease in 78 patients (33.9%), and unclassified IBD in 6 patients (2.6%). The prevalence of CMV was 6.1% ( Conclusions: The study reveals that the prevalence of EBV in the intestinal mucosa is high in patients with IBD and correlates with disease activity and severity, while HHV-6 is associated with specific immunosuppressive therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.